Development of a Pharmacy Collaborative Practice Agreement to Improve Efficiency and Management of Prescribing in a Renal Transplant Clinic

R. Chelewski, K. Johnson, A. Zuckerman, J. Declerq, L. Choi, M. Peter, A. Langone

Vanderbilt University Medical Center Nashville, TN



ATC2019 JUNE 1-5, 2019 • BOSTON, MA

JOHN B. HYNES CONVENTION CENTER

The Joint Annual Congress of the American Society of Transplant Surgeons and The American Society of Transplantation

Anthony Langone, MD FAST
Associate Professor of Medicine
Medical Director of the Medical Specialties Clinic
Vanderbilt University Medical Center, Nashville, TN

Rachel Chelewski, PharmD, CSP
Clinical Pharmacist
Vanderbilt Transplant Pharmacy
Vanderbilt University Medical Center, Nashville, TN

There are no financial relationships with commercial interests to disclose.



This presentation does not include discussion of offlabel or investigational use.



Development and Initiation of a Pharmacy Collaborative Practice Agreement



- Transplant Pharmacy started in July 2015
- Pharmacy Services embedded a clinical pharmacist in the Renal Transplant Clinic to help convert patients to using the Transplant Pharmacy, provide medication management, and relieve nurse and provider burden with refill requests
- A second pharmacist was added in December 2016



Development and Initiation of a Pharmacy Collaborative Practice Agreement

TN Pharmacists Association and TN Medical Association finalized legislation approving collaborative pharmacy practice agreements (CPPAs)

7/2015 Vanderbilt Renal Transplant Clinic & Vanderbilt Transplant Pharmacy developed a CPPA

Vanderbilt University Medical Center (VUMC) Pharmacy, Therapeutics, & Diagnostics Committee and VUMC Medical Board approved proposed CPPA

11/2016 VUMC legal department defined the CPPA and auditing requirements

2/2017 TN Board of Pharmacy and the TN State Attorney General approved the CPPA

3/2017 CPPA initiated in the VUMC Renal Transplant Clinic





Development and Initiation of a Pharmacy Collaborative Practice Agreement


- What does the Renal Transplant CPPA allows Pharmacists to do?
 - Refill any non-controlled medication that is being prescribed by a renal transplant physician if the patient has been seen by the provider within the past 12 months
 - Send in scripts for new medications or dose adjustments as documented in patients' electronic medical records
 - Refills may be prescribed by the pharmacist for up to one year
 - Pharmacists may discontinue & taper medications per protocol



Development and Initiation of a Pharmacy Collaborative Practice Agreement


- 319 patients included
- 2,349 prescriptions reviewed during study
- Immunosuppressant refills authorized by pharmacists increased to 85% after CPPA initiation

Immunosuppressant Prescription Refills by Authorizer Type





Development and Initiation of a Pharmacy Collaborative Practice Agreement



- Streamlined process from prescribing to dispensing
 - Pharmacists help facilitate financial assistance & other medication barriers
- Close medication monitoring for complex drug regimens by clinical pharmacists
- Physicians and nurses have more time to focus on direct patient care
- Transplant Pharmacy growth from 8 to 24 team members
- Over 11,000 scripts filled by the Transplant Pharmacy in April 2019
- Currently filling medications for over 1,100 renal transplant patients

Development and Initiation of a Pharmacy Collaborative Practice Agreement

2018 Patient Reported Outcomes

- Over 99% of patients reported they were "satisfied" or "extremely satisfied" with the services provided by the Transplant Pharmacy.
- Over 99% of patients reported they received services in a timely manner, their needs were met, and that overall communication with the Transplant Pharmacy was effective.

CPPA Safety Outcomes

- Monthly audits are performed by each physician on 5% of their patients covered under the CPPPA
- Quarterly audit reviews are held by collaborating pharmacists, the clinic medical director, and pharmacy administration
- No safety concerns have been identified



Contact Information

Rachel Chelewski, PharmD, CSP

Email: Rachel.Chelewski@vumc.org

Anthony Langone, MD FAST

Email: Anthony.Langone@vumc.org

